Search clinical trials for: BPI-7711

Total 1348 results

Beta Pharma, Inc.

Completed

A Phase I Study to Determine the Effect of Food on the Pharmacokinetic Profile of BPI-7711

NSCLC

China
Beta Pharma Shanghai

Completed

A Phase IIb Study of BPI-7711 Capsule in Non-small Cell Lung Cancer Patients With T790M Mutation Positive

NSCLC

China
Beta Pharma Shanghai

Completed

BPI-7711 Capsule in Patients With EGFR Mutation T790M Positive Non-small Cell Lung Cancer

Non-small Cell Lung Cancer

China
Beta Pharma Shanghai

Active, not recruiting

A Study of BPI-7711 Capsule in Non-small Cell Lung Cancer Patients

NSCLC

China
US Department of Veterans Affairs

Completed

Veterans Intensive Personalized Treatment in Heart Failure (VIP)

Heart Failure

United States
BeyondSpring Pharmaceuticals Inc.
Covance; ICON plc

Completed

Plinabulin vs. Pegfilgrastim in Patients With Solid Tumors Receiving Docetaxel Myelosuppressive Chemotherapy Phase 3 (Protective-1)

Chemotherapy-induced Neutropenia

China, Russian Federation, United States, Ukraine
Betta Pharmaceuticals Co., Ltd.

Not yet recruiting

A Study of BPI-452080 in Subjects With Solid Tumors

Renal Cell Carcinoma | Solid Tumor | Von Hippel-Lindau Disease

China
Xcovery Holding Company, LLC

Not yet recruiting

BPI-361175 Tablets in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

Non-small Cell Lung Carcinoma
Betta Pharmaceuticals Co., Ltd.

Not yet recruiting

A Phase 1 Study of BPI-371153 in Subjects With Advanced Solid Tumors or Relapsed/Refractory Lymphoma

Lymphoma | HCC | NSCLC | Advanced Solid Tumor

China
University of Texas Southwestern Medical Center

Terminated

Pharmacokinetic Response to BPI in Burns

Burns

United States
Betta Pharmaceuticals Co., Ltd.

Not yet recruiting

Phase 1 Study of BPI-442096 in Advanced Solid Tumor Patients

Colorectal Cancer | Pancreatic Cancer | Solid Tumor | Non-small Cell Lung Cancer

China
Betta Pharmaceuticals Co., Ltd.

Recruiting

A Phase 1 Study of BPI-28592 in Subjects With Advanced Solid Tumors

Metastasis, Neoplasm

China
Betta Pharmaceuticals Co., Ltd.

Recruiting

A Phase I Study of BPI-16350 in Patients With Advanced Solid Tumor

Advanced Solid Cancer

China
Assistance Publique Hopitaux De Marseille

Unknown

Study of the Prevalence of Painful Symptoms of the Musculoskeletal System After Lung Transplantation

Respiratory Insufficiency

France
Betta Pharmaceuticals Co., Ltd.

Recruiting

A Study of BPI-460372 in Advanced Solid Tumor Patients

Advanced Solid Tumor

China
Betta Pharmaceuticals Co., Ltd.

Recruiting

A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of BPI-21668

Advanced Solid Tumor

China
Betta Pharmaceuticals Co., Ltd.

Recruiting

A Phase 1/2 Study of BPI-361175 in Subjects With Advanced Solid Tumors

Non-small Cell Lung Cancer

China
Betta Pharmaceuticals Co., Ltd.

Recruiting

A Phase 1，Open-label Study of BPI-421286 in Subjects With Advanced Solid Tumors

Metastatic Cancer | Malignant Neoplasms

China
Betta Pharmaceuticals Co., Ltd.

Completed

A Food-Effect Study of BPI-16350 in Healthy Subjects

Healthy

China
Betta Pharmaceuticals Co., Ltd.

Unknown

Dose Escalating Study of BPI-3016 in Healthy Subjects

Healthy Subject

China
Zhejiang University

Unknown

Icotinib in Previously Treated Non/Light-smoking Patients With Advanced Squamous Cell Lung Cancer

Squamous Cell Carcinoma of Lung

China
University Hospital Tuebingen

Completed

Studying Non-motor Symptoms in HSP

SPG4

Germany
Betta Pharmaceuticals Co., Ltd.

Completed

Icotinib as an Adjuvant Therapy for Patients With Stage IIA-IIIA Adenocarcinoma With EGFR Mutation (ICAPE)

Non-small Cell Lung Cancer

China
Betta Pharmaceuticals Co., Ltd.

Completed

Second-line Treatment With Icotinib in Esophageal Carcinoma Patients With EGFR Overexpression (IHC 3+) or Positive FISH

Esophageal Carcinoma | Adenocarcinoma of the Gastroesophageal Junction

China
Betta Pharmaceuticals Co., Ltd.

Unknown

Icotinib in Advanced Non-small Cell Lung Cancer (NSCLC) With Hepatic Insufficiency

Non-small Cell Lung Cancer

China
Gönül GÖKÇAY

Completed

Education-Based İntervention Program for Persons With Chronic Obstructive Pulmonary Disease (EBIPCOPD)

Chronic Obstructive Pulmonary Disease

Turkey
Betta Pharmaceuticals Co., Ltd.

Unknown

First-line Treatment With Icotinib in Elder NSCLC EGFR Mutated Patients

Non-Small Cell Lung Cancer

China
Betta Pharmaceuticals Co., Ltd.

Completed

Dose Escalation Of Icotinib In Previously Treated Patients With Routine Dose

Non-small Cell Lung Cancer

China
Betta Pharmaceuticals Co., Ltd.

Unknown

Icotinib Versus Placebo as Adjuvant Therapy in EGFR-mutant Lung Adenocarcinoma (ICWIP)

Adenocarcinoma | EGFR Positive Non-small Cell Lung Cancer

China
Bayer

Completed

An Evaluation of a Gender Specific Insole to Provide Relief From Knee Pain Due to Osteoarthritis or General Anterior Knee Pain in Male Subjects When Used in Foot Wear Over a Period of Four Weeks

Osteoarthritis, Knee

United States
Betta Pharmaceuticals Co., Ltd.

Completed

Safety and Pharmacokinetics of BPI-9016M in Patients With Advanced Solid Tumors

Solid Tumors

China
GlaxoSmithKline

Completed

Benign Prostatic Hyperplasia (BPH) Screening Tool Case Finding Study in Subjects >=50 Years

Prostatic Hyperplasia

Germany, Russian Federation, Spain, Italy, France
Kissei Pharmaceutical Co., Ltd.

Completed

Phase II Study of KWA-0711 in Patients With Chronic Constipation (CC)

Chronic Constipation

Japan
Betta Pharmaceuticals Co., Ltd.

Unknown

Icotinib With Whole Brain Radiation Therapy in NSCLC Patients With Brain Metastases

Non-small-cell Lung Cancer

China
Betta Pharmaceuticals Co., Ltd.

Unknown

Sequential Icotinib Plus Chemotherapy Versus Icotinib Alone as First-line Treatment in Stage IIIB/IV Lung Adenocarcinoma

Adenocarcinoma | EGFR Positive Non-small Cell Lung Cancer

China
Bayer

Completed

Study to Test the Usability of a New Injector to Administer Contrast Media Into Humans for Diagnostic Purposes (PERCENT)

Computed Tomography

Australia, Netherlands
Kissei Pharmaceutical Co., Ltd.

Completed

A Single-blind, Dose-tapering Study of KWA-0711 in Patients With Chronic Constipation

Chronic Constipation

Japan
National Institute of Neurological Disorders and...

Completed

Safety, Tolerability, and Effectiveness of CGP77116 in Patients With Multiple Sclerosis (MS)

Multiple Sclerosis

United States
Kissei Pharmaceutical Co., Ltd.

Completed

Phase II Dose-Finding Study of KWA-0711 in Patients With Chronic Constipation (CC)

Chronic Constipation

Japan
Kissei Pharmaceutical Co., Ltd.

Completed

Study of Absorption, Metabolism and Excretion Following a Single Oral Dose of [14C]KWA-0711 to Healthy Male Subjects

Healthy Male Subject

United Kingdom
Beta Pharma, Inc.

Completed

A Phase I Study to Assess the Effect of Itraconazole and Rifampicin on Pharmacokinetics Profile of BPI-7711

NSCLC

China
Betta Pharmaceuticals Co., Ltd.

Recruiting

Safety, Efficacy and Pharmacokinetic of BPI-9016M in Patients With c-Met- Dysregulated Advanced NSCLC

Non-small Cell Lung Cancer

China
Kissei Pharmaceutical Co., Ltd.

Completed

A Single-blind, Dose-titration Study of KWA-0711 in Patients With Chronic Constipation

Chronic Constipation

Japan
Kissei Pharmaceutical Co., Ltd.

Completed

A Exploratory Study of KWA-0711 in Patients With Chronic Idiopathic Constipation (CIC)

Chronic Idiopathic Constipation

Japan
Betta Pharmaceuticals Co., Ltd.

Completed

Safety, Tolerability and Pharmacokinetic Profile of BPI-15086 in EGFR T790M Mutation-positive NSCLC Patients

Non-Small Cell Lung Cancer

China
Sun Yat-sen University

Recruiting

Icotinib for Completed Resected IB NSCLC With EGFR Mutation (CORIN)

Lung Neoplasms | Bronchial Neoplasms | Squamous Cell Lung Cancer | Adenocarcinoma of the Lung | Large Cell Lung Cancer | Adenosquamous Cell Lung Cancer | Stage IB Non-small Cell Lung Cancer

China
University of California, Davis

Completed

Casinomacropeptide and Satiety (CMP2)

Appetite Disorders | Lack of Satiety | Excess Intake of Macronutrients

United States
Bayer

Completed

Efficacy/Safety Study to Confirm Iberogast's Efficacy in Patients With Irritable Bowel Syndrome Diagnosed on ROME III Criteria Compared to Placebo

Irritable Bowel Syndrome

Germany
Bayer

Completed

A Pharmacy-based Study to Learn More About How Well Iberogast Works, How it Affects the Body, How it is Used, and User Satisfaction in Patients With Functional and Motility-related (Stomach and Bowel Movement-related) Gastrointestinal Diseases, Including Irritable Bowel Syndrome

Functional and Motility Related Gastrointestinal Disorders Such as Irritable Bowel Syndrome and Functional Dyspepsia

Germany
Betta Pharmaceuticals Co., Ltd.

Suspended

Increased Dose of Icotinib in Advanced None Small Cell Lung Cancer Patients After Routine Gefitinib Therapy

Non-small Cell Lung Cancer

China

3

Subscribe